{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:17:02Z","timestamp":1780359422469,"version":"3.54.1"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,2,13]],"date-time":"2012-02-13T00:00:00Z","timestamp":1329091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Rheumatoid arthritis (<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>) is a chronic, systemic inflammatory disorder affecting synovial joints and many other organs. Most patients seen in clinical settings have a progressive chronic disease, with radiographic damage, frequent work disability, incremental functional declines and increased mortality rates. The introduction of the biological drugs in treatment of <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> has played an important role in prevention of destructive effects of the disease but may have serious adverse effects due to their powerful inhibition of the immune system.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To study the adverse effects (<jats:styled-content style=\"fixed-case\">ADE<\/jats:styled-content>s) of three different tumor necrosis factor \u03b1 inhibitor (<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>i) drugs (infliximab, adalimumab and etanercept) in <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients for 5\u00a0years in the south\u2010west area of <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>audi <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>rabia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Two groups of <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients were included in this study: The first group included 112 patients, representing the biologics group. These patients received biological therapy plus disease modifying anti\u2010rheumatic drugs (<jats:styled-content style=\"fixed-case\">DMARD<\/jats:styled-content>s): 56 patients received infliximab (<jats:styled-content style=\"fixed-case\">IFX<\/jats:styled-content>), 36 patients received adalimumab (<jats:styled-content style=\"fixed-case\">ADL<\/jats:styled-content>) and 20 patients received etanercept (<jats:styled-content style=\"fixed-case\">ETN<\/jats:styled-content>). The second group also included 112 patients, representing the control group: <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients treated only with the traditional <jats:styled-content style=\"fixed-case\">DMARD<\/jats:styled-content>s. <jats:styled-content style=\"fixed-case\">ADE<\/jats:styled-content>s were classified into mild and severe.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mild <jats:styled-content style=\"fixed-case\">ADE<\/jats:styled-content>s which had been recorded during 5\u00a0years of follow\u2010up in patients receiving <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>i, were onycholysis (1.8%), positive tuberculin test (1.8%) and small vessel vasculitis (1.8%). Statistically, there were insignificant differences in the mild <jats:styled-content style=\"fixed-case\">ADE<\/jats:styled-content>s except for upper respiratory tract infection that was significantly higher in the control group. Severe <jats:styled-content style=\"fixed-case\">ADE<\/jats:styled-content>s included pneumonia (1.8%) and solid tumor (1.8%) and there were no significant differences between the biologics and control groups. Also there were no significant statistical differences for the <jats:styled-content style=\"fixed-case\">ADE<\/jats:styled-content>s, mild or severe, between the three biologics, infliximab, adalimumab and etanercept. Occurrence of <jats:styled-content style=\"fixed-case\">ADE<\/jats:styled-content>s did not correlate to methotrexate dose, steroid dose or rheumatoid factor positivity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our results indicate that the use of <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>i therapy appeared to be as safe as traditional <jats:styled-content style=\"fixed-case\">DMARD<\/jats:styled-content>s in treatment of rheumatoid arthritis patients and long\u2010term follow\u2010up with careful examination is essential to pick up any abnormal <jats:styled-content style=\"fixed-case\">ADE<\/jats:styled-content>s.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1756-185x.2012.01715.x","type":"journal-article","created":{"date-parts":[[2012,2,13]],"date-time":"2012-02-13T08:07:25Z","timestamp":1329120445000},"page":"330-335","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Lack of adverse effect of anti\u2010tumor necrosis factor\u2010\u03b1 biologics in treatment of rheumatoid arthritis: 5\u00a0years follow\u2010up"],"prefix":"10.1111","volume":"15","author":[{"given":"Ahmed M.","family":"Dewedar","sequence":"first","affiliation":[{"name":"Department of Rheumatology Suez Canal University Ismailia Egypt"},{"name":"Ministry of Health Abha, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medhat A.","family":"Shalaby","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Al\u2010Azhar University Cairo Egypt"},{"name":"Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulaiman","family":"Al\u2010Homaid","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Al\u2010Azhar University Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Mahfouz","sequence":"additional","affiliation":[{"name":"Department of Epidemiology King Khalid University Abha Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama A.","family":"Shams","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Suez Canal University Ismailia Egypt"},{"name":"Ministry of Health Abha, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Fathy","sequence":"additional","affiliation":[{"name":"Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,2,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.2217\/ijr.09.70"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400302"},{"issue":"28","key":"e_1_2_6_4_1","first-page":"S152","article-title":"Side effects of anti\u2010TNF therapy: current knowledge","volume":"20","author":"Antoni C","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.58"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275"},{"key":"e_1_2_6_7_1","first-page":"2398","article-title":"The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systemic review and meta\u2010analysis","volume":"33","author":"Gartlehner G","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_6_8_1","first-page":"1035","article-title":"Clinical use of anti TNF\u2010\u03b1 biological agents. A guide for GPs","volume":"36","author":"Chang J","year":"2007","journal-title":"Aust Fam Physician"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.2174\/157339711794474620"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1998.4610"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.091025"},{"key":"e_1_2_6_12_1","first-page":"124","article-title":"Anti\u2010TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6\u00a0months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly","volume":"51","author":"Galloway JB","year":"2010","journal-title":"Rheumatology"},{"key":"e_1_2_6_13_1","first-page":"1436","article-title":"Increased risk of tuberculosis in patients with rheumatoid arthritis","volume":"30","author":"Carmona L","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-004-1037-x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-004-0281-x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.047274"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2004.11.006"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.043166"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.118935"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21137"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1086\/506935"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24632"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22768"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01891.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.146"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2007.10.011"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1086\/598331"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23112"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.10.002"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.083188"},{"key":"e_1_2_6_31_1","first-page":"CD007848","article-title":"Biologics for rheumatoid arthritis: an overview of Cochrane reviews","author":"Singh JA","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.091025"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094904"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e328344a732"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.11.023"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1756-185X.2012.01715.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1756-185X.2012.01715.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T17:22:07Z","timestamp":1698772927000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1756-185X.2012.01715.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,13]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1111\/j.1756-185X.2012.01715.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1756-185x.2012.01715.x","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,13]]},"assertion":[{"value":"2012-02-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}